Most companies developing CAR-T therapies are firmly focused on blood cancers, but Celyad is bucking the trend with a trial that will include a tougher…

Kitov Pharmaceuticals has bought a 56% stake in TyrNovo to take control of a cancer program.

Nivalis is laying off 80% of its staff including its CEO and CMO.

Troubled Insys bids farewell to founder and CEO John Kapoor, while ex-Biogen boss George Scangos takes the helm at infectious disease startup Vir Biotechnology.

CV9014 failed a phase 2b trial in prostate cancer, but the company says its efficacy could be unlocked if used alongside checkpoint inhibitors.

Biogen’s new spinoff Bioverativ will be trading on the Nasdaq next from the start of month with two products, $325 million in the bank, hundreds of staffers…

In this week's EuroBiotech Report, Merck KGaA buys Vertex oncology programs, three French drugmakers pen pipeline-building pacts and more.

In our EuroBiotech roundup this week, Celyad claims win in CAR-T patent scrap, I/O startup raises money, Kymab snags cash from Gates Foundation and more.

Ionis, fresh from its approval of Spinraza with Biogen, says it is seeking to get its heart drug volanesorsen in front of the FDA as soon as possible, as it…